Scholarlink

Background <p>Dysfunctional vascular access is a major cause of morbidity and mortality in patients undergoing hemodialysis, affecting both arteriovenous fistulas and grafts. The most optimal strategy to restore long-term patency has not been established. This meta-analysis compares drug-coated balloon (DCB) versus uncoated balloon (UCB) angioplasty for dysfunctional vascular access.</p> Methods <p>We performed a systematic literature search across multiple databases from inception to June 2024. Randomized-controlled trials (RCTs) comparing DCB and UCB in dialysis patients with dysfunctional vascular access were included. Risk ratios were pooled using a random-effects model.</p> Results <p>Twenty-seven RCTs (2645 patients) were included. Target lesion patency (TLP) at 6&#xa0;months was significantly superior in the DCB group (RR 1.22, 95% CI 1.07–1.39, <i>p</i> = 0.003). The two regimens were comparable for TLP at 3&#xa0;months (RR 1.14, <i>p</i> = 0.24) and 12&#xa0;months (RR 1.14, <i>p</i> = 0.10). The two regimens were comparable in terms of circuit patency rate, target-lesion revascularization, and all-cause mortality.</p> Conclusion <p>DCB has significantly superior TLP and a comparable risk of mortality to UCB. Further research is warranted to identify factors affecting outcomes following DCB angioplasty for dysfunctional dialysis&#xa0;access.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of drug-coated balloon versus uncoated balloon for dysfunctional dialysis access: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年2月24日

查看全文
  • Aarij Elahi,
  • Momina Qamar,
  • Fasih Mand Khan,
  • Rameesha Babar,
  • Muhammad Jawad Zahid,
  • Muhammad Omar Ahmad,
  • Shah Wali,
  • Sharib Afzal,
  • Moeen Ikram,
  • Syed Ahsan Ali Shah,
  • Mohammad Ebad Ur Rehman,
  • Huzaifa Ahmad Cheema,
  • Usama Anwar,
  • Muhammad Mohid Tahir,
  • Ioannis Bellos

摘要

Background

Dysfunctional vascular access is a major cause of morbidity and mortality in patients undergoing hemodialysis, affecting both arteriovenous fistulas and grafts. The most optimal strategy to restore long-term patency has not been established. This meta-analysis compares drug-coated balloon (DCB) versus uncoated balloon (UCB) angioplasty for dysfunctional vascular access.

Methods

We performed a systematic literature search across multiple databases from inception to June 2024. Randomized-controlled trials (RCTs) comparing DCB and UCB in dialysis patients with dysfunctional vascular access were included. Risk ratios were pooled using a random-effects model.

Results

Twenty-seven RCTs (2645 patients) were included. Target lesion patency (TLP) at 6 months was significantly superior in the DCB group (RR 1.22, 95% CI 1.07–1.39, p = 0.003). The two regimens were comparable for TLP at 3 months (RR 1.14, p = 0.24) and 12 months (RR 1.14, p = 0.10). The two regimens were comparable in terms of circuit patency rate, target-lesion revascularization, and all-cause mortality.

Conclusion

DCB has significantly superior TLP and a comparable risk of mortality to UCB. Further research is warranted to identify factors affecting outcomes following DCB angioplasty for dysfunctional dialysis access.